Market Survey Shows Potential of JAK Inhibitors to Treat IBD

Market Survey Shows Potential of JAK Inhibitors to Treat IBD
Directors from pharmaceutical and health insurance companies and gastroenterologists in the United States have expressed a positive opinion overall about the use of janus kinase (JAK) inhibitors for the treatment of inflammatory bowel disease (IBD), according to a recent survey. In the United States, TNF-α inhibitors, such as Remicade (infliximab) and Humira (adalimumab), are commonly used to treat ulcerative colitis and Crohn’s disease. However, the development of new therapies has brought alternative options to the market, especially for patients who do not respond to or cannot receive TNF-α inhibitors. This has begun to change the IBD treatment paradigm. "Drugmakers looking to compete in the IBD market need to overcome the entrenched favorable reimbursement status of the long-marketed TNF inhibitors. That said, gastroenterologists are excited about the JAK inhibitors' potential in a market where many patients are refractory to treatments already available although use may be relegated to later lines," Brian Nasipak, an analyst at Decision Resources Group, said in a press release. To provide a more informed and accurate state of the market regarding the real position of each of the available or potential therapies to treat patients with IBD, the Decision Resources Group conduct
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *